CalciMedica (CALC) Competitors $2.78 -0.01 (-0.36%) Closing price 08/22/2025 03:58 PM EasternExtended Trading$2.80 +0.02 (+0.72%) As of 08/22/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. BTMD, GLSI, BHST, CRDF, ELDN, MEIP, BDTX, THTX, CABA, and MCRBShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include biote (BTMD), Greenwich LifeSciences (GLSI), BioHarvest Sciences (BHST), Cardiff Oncology (CRDF), Eledon Pharmaceuticals (ELDN), MEI Pharma (MEIP), Black Diamond Therapeutics (BDTX), Theratechnologies (THTX), Cabaletta Bio (CABA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors biote Greenwich LifeSciences BioHarvest Sciences Cardiff Oncology Eledon Pharmaceuticals MEI Pharma Black Diamond Therapeutics Theratechnologies Cabaletta Bio Seres Therapeutics biote (NASDAQ:BTMD) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends. Which has preferable earnings & valuation, BTMD or CALC? biote has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$199.07M0.80$3.16M$0.903.58CalciMedicaN/AN/A-$13.70M-$1.60-1.74 Is BTMD or CALC more profitable? biote has a net margin of 15.73% compared to CalciMedica's net margin of 0.00%. biote's return on equity of -21.00% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets biote15.73% -21.00% 18.26% CalciMedica N/A -206.51%-103.81% Do analysts prefer BTMD or CALC? biote presently has a consensus target price of $6.00, indicating a potential upside of 86.34%. CalciMedica has a consensus target price of $16.00, indicating a potential upside of 475.54%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts plainly believe CalciMedica is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in BTMD or CALC? 21.7% of biote shares are held by institutional investors. 24.0% of biote shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, BTMD or CALC? biote has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Does the media favor BTMD or CALC? In the previous week, CalciMedica had 13 more articles in the media than biote. MarketBeat recorded 13 mentions for CalciMedica and 0 mentions for biote. CalciMedica's average media sentiment score of 0.85 beat biote's score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media. Company Overall Sentiment biote Neutral CalciMedica Positive Summarybiote beats CalciMedica on 7 of the 13 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.84M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E RatioN/A21.2831.3626.05Price / SalesN/A347.16434.71196.83Price / CashN/A43.1937.7358.48Price / Book6.328.129.536.61Net Income-$13.70M-$54.72M$3.26B$265.65M7 Day Performance-4.47%2.62%2.12%2.02%1 Month Performance-33.81%2.68%2.80%-0.32%1 Year Performance-32.36%10.93%30.68%19.06% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.3138 of 5 stars$2.78-0.4%$16.00+475.5%-33.5%$38.84MN/A0.0030BTMDbiote2.2228 of 5 stars$3.13+3.6%$6.00+91.7%-44.0%$154.99M$197.19M3.48194GLSIGreenwich LifeSciences1.6849 of 5 stars$11.55-3.8%$39.00+237.7%-13.9%$154.41MN/A-8.493Trending NewsAnalyst ForecastAnalyst RevisionBHSTBioHarvest SciencesN/A$9.35-2.6%$13.67+46.2%N/A$153.53M$25.19M-13.36N/ACRDFCardiff Oncology1.5818 of 5 stars$2.31-5.1%$10.10+338.2%+1.3%$153.35M$680K-2.6520Positive NewsELDNEledon Pharmaceuticals1.4811 of 5 stars$2.55-2.1%$10.00+292.9%-11.9%$152.40MN/A-2.1810Short Interest ↑MEIPMEI Pharma1.3368 of 5 stars$4.71-3.6%N/A+58.8%$152.30M$65.30M-0.99100News CoverageAnalyst UpgradeBDTXBlack Diamond Therapeutics3.2028 of 5 stars$2.64-4.2%$12.40+370.6%-52.3%$150.04MN/A11.4690THTXTheratechnologiesN/A$3.24-0.5%N/A+158.7%$148.75M$84.38M-17.03140News CoverageShort Interest ↓CABACabaletta Bio2.087 of 5 stars$1.63-8.2%$14.43+787.9%-72.1%$148.62MN/A-0.6050MCRBSeres Therapeutics3.2487 of 5 stars$16.89-4.5%$73.67+336.1%+13.0%$147.91MN/A-3.67330 Related Companies and Tools Related Companies biote Alternatives Greenwich LifeSciences Alternatives BioHarvest Sciences Alternatives Cardiff Oncology Alternatives Eledon Pharmaceuticals Alternatives MEI Pharma Alternatives Black Diamond Therapeutics Alternatives Theratechnologies Alternatives Cabaletta Bio Alternatives Seres Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access